M. Gadhikar, J. Myers
2018
Citations
0
Influential Citations
0
Citations
Journal
Molecular Cancer Therapeutics
Abstract
Prexasertib, a highly potent Chk1 inhibitor, has shown remarkable single-agent activity (IC50 Citation Format: Mayur A. Gadhikar, Jeffrey N. Myers. Gemcitabine cotreatment enhances the therapeutic effect of prexasertib in HNSCC cells that are less sensitive to Chk1 inhibition single-agent therapy [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A073.